
Ogivri (trastuzumab-dkst) has been approved by the U.S. Food and Drug Administration as the nation’s first biosimilar drug to treat certain breast and stomach cancers, the agency said Friday in a news release. The maker of a biosimilar, derived from a living organism, must demonstrate that the new product is “highly similar” to an already… read on >